Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shandong Henglu Biotech Co. Ltd. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and the same number of distinct art units. This distribution indicates that each pending matter is being handled by a different examiner in a different department, which may lead to varying prosecution timelines.
LAU, JONATHAN S is the busiest examiner for the portfolio, currently responsible for 1 pending office action. This means that the other pending action is assigned to a different examiner. The Biotechnology & Pharmaceuticals area often requires specialized knowledge, and the involvement of multiple examiners and art units suggests a diverse range of subject matter in the company's filings.
With the total pending office actions spread across the distinct art units, the company must manage its prosecution strategy to ensure consistency. Although LAU, JONATHAN S is the busiest examiner with 1 action, the overall workload is split between the examiners. Practitioners should monitor the distinct examiners to identify any specific requirements or trends that could affect the outcome of the total pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
| HUTSON, RICHARD G | 1 | 65.1% | +52.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718291 | NEW CRYSTAL FORM OF TRISACCHARIDE | LAU, JONATHAN S | — |
| 18706827 | RECOMBINANT YEAST AND APPLICATION THEREOF | HUTSON, RICHARD G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706827 | RECOMBINANT YEAST AND APPLICATION THEREOF | HUTSON, RICHARD G | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718291 | NEW CRYSTAL FORM OF TRISACCHARIDE | LAU, JONATHAN S | 1693 | §102§103§112 | Non-Final OA | — | Pending | Jun 10, 2024 |
| 18706827 | RECOMBINANT YEAST AND APPLICATION THEREOF | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShandong Henglu Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jonathan S Lau has the most, with 1 of Shandong Henglu Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
